Small (Weinheim an der Bergstrasse, Germany) · 2025
Bispecific Peptide Binds to VEGFR2 and Integrin αvβ3, Forming an Artificial Extracellular Matrix for Anti-Ocular Neoangiogenesis.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Ye, Zhang Kuo, Xu Ling, Lu Xinmin, Hu Ping, Long Jinyi, Cui Ning, Wu Xue, Ye Yuhong, Xu Guo-Yang, Zhang Qing-Shi, Wang Lei, Hu Ying, Wang Hao, Long Da
Аннотация
Ocular neovascularization (NV) leads to vision loss in various pathological conditions. Current therapies primarily inhibit vascular endothelial growth factor (VEGF) signaling; however, targeting additional pathways may improve outcomes. A bispecific peptide (BsPt) is developed that targets VEGFR2 and integrin αvβ3 to treat retinal neovascularization (RNV) and choroidal neovascularization (CNV) more effectively. BsPt binds to both receptors on endothelial cells (ECs) and forms nanofibrous networks on their surfaces, resulting in potent NV inhibition. In vitro, BsPt suppressed retinal EC migration and tube formation. Intravitreal BsPt injection outperformed aflibercept in mouse models of oxygen-induced retinopathy (OIR) and laser-induced CNV. RNA sequencing revealed that BsPt-induced nanofibers upregulated extracellular matrix (ECM) and cell adhesion genes, which may contribute to anti-angiogenesis and anti-leakage effects. In summary, BsPt targeting VEGFR2 and integrin αvβ3 demonstrates enhanced therapeutic potential for RNV and CNV.